Axsome Therapeutics, Inc
AXSMAxsome Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative medicines for the treatment of central nervous system (CNS) disorders, including depression, migraine, and Parkinson's disease. The company aims to address unmet medical needs through novel proprietary compounds and formulations.
Company News
Two biotech companies are highlighted as standout investments for 2026. Axsome Therapeutics has strong late-stage pipeline developments with FDA acceptance of supplemental applications for AXS-05 in Alzheimer's agitation treatment and support for AXS-12 for narcolepsy, with 19 of 20 analysts rating it a Buy and targeting 8% upside. Innoviva recei...
The Motley Fool recommends two biotech stocks for long-term investment: Axsome Therapeutics, which has generated strong revenue growth (65.8% YoY through Q3 2025) with approved products and promising late-stage candidates including Auvelity for Alzheimer's disease agitation; and Exelixis, an oncology specialist with its blockbuster drug Cabometyx...
Axsome Therapeutics announced that the FDA has accepted and granted Priority Review designation to its supplemental NDA for AXS-05 for treating Alzheimer's disease agitation, with a PDUFA target action date of April 30, 2026. The drug addresses a significant unmet medical need, as up to 76% of Alzheimer's patients experience agitation. AXS-05 pre...
The article highlights two biotechnology companies, Therapeutics and Exelixis, as promising investment opportunities for 2026 due to their innovative drug pipelines and potential for significant market growth.
Axsome Therapeutics will participate in two investor conferences in December 2025, including the Piper Sandler Healthcare Conference and BofA Securities CNS Therapeutics Virtual Conference, presenting their latest developments in central nervous system treatments.
